Our mission is one of both public health and patient welfare.

To improve quality of life for patients, providing meaningful interventions

by way of Autologous Cell-Based Preparations & Tissue Engineering.


Regen Lab is a leading innovator of medical device in the field of products intended for autologous regenerative medicine, based on an extemporaneous preparation of Platelet-Rich Plasma (PRP, autologous thrombin…) from the patient’s blood, cell therapy (in particular extract MSCs from bone marrow) and combined therapy (PRP combined with hyaluronic acid).

To date, Regen Lab’s patented technologies are available in over 160 countries worldwide, and have been used to treat over 2 million patients in various therapeutic areas (musculoskeletal, dermal, wound care and intimacy)leading to the publication of over 120 research projects.

Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacture of high-quality medical devices, intended for the preparation of autologous cellular therapies prepared from the patient’s own blood, especially platelet-rich plasma.

In 2009, a Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland allowing RegenLab® to increase access to autologous cellular therapies around the world.

The majority of our medical devices are now Developed and Manufactured in the USA, in Brooklyn, as of November 2021.

Developed & Manufactured in the USA

In November of 2021, RegenLab® USA began production of RegenKit® Medical Devices in a new facility housed within BioBAT, a life sciences incubator based out of Brooklyn Army Terminal.
This allows us to further solidify ease of access to our products, as well as further ensure the highest-quality standards.

Since then, the majority of our products have been Manufactured in the USA, with further developments forthcoming due to important academic partnerships formed both in the U.S. and abroad.

Outcome-Informed Approaches

At the core of RegenLab’s business model lies in our R&D department, which has enabled the development of advanced technologies for the purpose of expanding knowledge in and accessibility of meaningful advancements in the field of Regenerative Medicine.

The human body is host to an intricate and powerful biological machinery, which (in a healthy individual) can easily replace damaged cells and tissues given the proper rest and nutrition.
Unfortunately, as we age or suffer repetitive injuries, this machinery can become somewhat impaired in affected areas

Our solution to this comes in the form of RegenKit® medical devices which allow selective harvesting of specific blood components, directly from the patient, for safe and rapid preparation to be applied by a properly-trained provider.
RegenLab’s mission is to provide meaningful interventions, which considerably improve quality of life , while minimizing potential side effects.

With this comes the RegenPRP™ methodology to standardize biological preparations and provide educational resources in the field of autologous cellular therapies, facilitated by outcome-informed approaches and technological innovation. 

Learn More about RegenPRP™


As we look to the future, we remain committed to the development of standardized practices for emerging categories within Regenerative Medicine, for the benefit of public health and patient welfare.


Contact Regenlab® USA

Now is the time to step into the future of medicine.

Join the Generation! 

| REGENeration |


Get connected with us to Learn More.

For more information on our products, please contact us by clicking on the button below:


Our Affiliated Locations:

  • New York (USA)
  • Montréal (Canada)
  • Venice (Italy)
  • Munich (Germany)
  • Paris (France)
  • Dubai (U.A.E.)
  • Beijing (China)
  • Istanbul (Turkey)